跳转至内容
Merck
CN

EHU056221

MISSION® esiRNA

targeting human COPB1

登录 查看组织和合同定价。

选择尺寸


关于此项目

NACRES:
NA.51
UNSPSC Code:
41105324
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

MISSION® esiRNA, targeting human COPB1

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

TCCTGTTCTGTCCGATTTCCAGATATGGCTGCAAATGTTATTCCTGTGTTAATGGAATTTCTCAGTGACAACAACGAAGCAGCAGCTGCTGATGTCTTGGAGTTTGTTCGTGAAGCCATTCAGCGCTTTGATAACCTGAGAATGCTTATTGTTGAGAAGATGCTTGAAGTCTTTCATGCTATTAAATCTGTCAAGATTTACCGAGGAGCATTATGGATCCTGGGAGAATACTGTAGTACCAAGGAAGACATTCAGAGTGTGATGACTGAGATCCGCAGGTCCCTTGGAGAGATCCCAATTGTAGAGTCAGAAATAAAGAAAGAAGCTGGTGAATTAAAACCTGAAGAAGAAATAACTGTAGGGCCAGTTCAGAAATTGGTTACTGAAATGGGTACCTATGCAACTCAGAGTGCCCTTAGCAGTTCTAGACCCACCAAGAAAGAGGAA

Ensembl | human accession no.

NCBI accession no.

shipped in

ambient

storage temp.

−20°C

Quality Level

Gene Information

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Nisha Bte Mohd Rafiq et al.
The Journal of cell biology, 216(1), 181-197 (2016-12-23)
Podosomes represent a class of integrin-mediated cell-matrix adhesions formed by migrating and matrix-degrading cells. We demonstrate that in macrophage-like THP1 cells and fibroblasts stimulated to produce podosomes, down-regulation of the G-protein ARF1 or the ARF1 guanine nucleotide exchange factor, ARNO
Hiroki Kobayashi et al.
Biochemical and biophysical research communications, 467(1), 121-127 (2015-09-26)
Combining glycolytic inhibition with other anti-cancer therapies is a potential approach to treating cancer. In this context, we attempted to identify genes that determine sensitivity to 2-deoxyglucose (2DG), a glycolytic inhibitor, in cancer cells using pooled shRNA libraries targeting ∼15,000

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持